Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.56 |
| ▸ | CYP3A5 | P20815 | 13/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3296784 | 0.89 | CYP3A4 (0.41) | CYP3A4CYP3A5CYP19A1ALDH1A1POLB | |
| SCHEMBL4027420 | 0.89 | CYP3A4 (0.40) | CYP3A4CYP3A5CYP19A1FNTAFNTB | |
| SCHEMBL8263917 | 0.89 | CYP3A4 (0.37) | CYP3A4CYP3A5CYP19A1ALDH1A1 | |
| SCHEMBL4028768 | 0.86 | CYP3A4 (0.41) | CYP3A4CYP3A5ALDH1A1POLB | |
| SCHEMBL2906358 | 0.81 | CYP3A4 (0.54) | CYP3A4CYP3A5CYP19A1FNTAFNTB | |
| SCHEMBL2905664 | 0.81 | CYP3A4 (0.54) | CYP3A4CYP3A5CYP19A1FNTAFNTB | |
| SCHEMBL2905660 | 0.81 | CYP3A4 (0.54) | CYP3A4CYP3A5CYP19A1FNTAFNTB | |
| SCHEMBL3297675 | 0.81 | POLB (0.35) | POLB | |
| SCHEMBL3294287 | 0.81 | POLB (0.35) | POLB | |
| SCHEMBL3295161 | 0.81 | POLB (0.35) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263720-B1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2009-06-03 | — | — | EP | claimed |
| US-20080221078-A1 | Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia | AVENTIS PHARMACEUTICALS INC. (US) | 2008-09-11 | — | — | US | claimed |
| EP-1962834-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | Aventis Pharmaceuticals Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067617-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | WO | claimed |
| EP-1263720-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | claimed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | claimed |
| EP-1263720-B1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2009-06-03 | — | — | EP | disclosed |
| US-20080221078-A1 | Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia | AVENTIS PHARMACEUTICALS INC. (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1962834-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | Aventis Pharmaceuticals Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070197654-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| WO-2007067617-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-7217705-B2 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2007-05-15 | — | — | US | disclosed |
| EP-1649849-A2 | Compositions for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates the dopaminergic neurotransmission in the brain. | Aventis Pharma S.A. (FR) | 2006-04-26 | — | — | EP | disclosed |
| US-20040209861-A1 | Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2004-10-21 | — | — | US | disclosed |
| EP-1423145-A1 | COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | Aventis Pharma S.A. (FR) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020314-A1 | COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | AVENTIS PHARMA S.A. (FR) | 2003-03-13 | — | — | WO | disclosed |
| EP-1263720-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209861-A1 | Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | CNR1, CNR2, GPR18 | CYP3A4 2401/4885CYP3A5 2498/4885CYP19A1 1740/4885 |
| US-20070197654-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE | CNR1, CNR2, GPR18 | CYP3A4 2489/4885CYP3A5 2608/4885CYP19A1 2026/4885 |
| US-20080221078-A1 | Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia | CNR1, CNR2, GPR139 | CYP3A4 3859/4885CYP3A5 1737/4885CYP19A1 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.